KIEL, Germany--(BUSINESS WIRE)--Dec. 13, 2005--The first phase in the clinical trial of the newly developed drug Elafin has been successfully completed as announced by Proteo Biotech AG, a wholly owned subsidiary of Proteo Inc. (OTCBB:PTEO). Elafin, a recombinant human protein, is intended for the treatment of inflammatory diseases and is administered intravenously. The trial aimed to assess the safety and tolerability of this biotechnologically manufactured drug.
